Applied BioMath's Scientific and Executive Leadership Teams recently spent the day at our Science and Strategy offsite. We reflected on 2015 projects, shared new science and technologies, and officially kicked off 2016. We are extremely proud of what we achieved in 2015, and we will work diligently to continue that momentum into and throughout 2016!
In The News
Applied BioMath (www.appliedbiomath.com) is thrilled to announce that Werner Meier is the newest member of its Scientific Advisory Board, which comprises pioneers and thought leaders in the mathematical modeling, biological engineering, biotechnology, and medical fields. Werner joins key opinion leaders Douglas Lauffenburger, PhD, Dr. Joseph Loscalzo, MD, PhD, Bruce Tidor, PhD, and Michael Yaffe, MD, PhD.
Applied BioMath, LLC (www.appliedbiomath.com) today announced a collaboration with Zymeworks Inc. (www.zymeworks.com), a leader in the development of bi-specific antibodies, to leverage Applied BioMath's proprietary analytical and predictive capabilities in quantitative systems pharmacology.
At Applied BioMath, we believe strongly in giving back to our community. One of our founding principles is to try and make the world a better place. Our products and services help our commercial partners make a better world through development of novel medicines, but our efforts shouldn’t stop there. Embedded in our corporate DNA is the commitment to help others less fortunate than ourselves. As a part of our Corporate Mission, Applied BioMath will partake in an annual Charitable Giving Program, donating a portion of our profits to charities selected by our team.
Dr. Joseph Loscalzo, MD, PhD announced as newest member of the Applied BioMath Scientific Advisory Board
Applied BioMath is thrilled to announce that Dr.Joseph Loscalzo, MD, PhD is the newest member if its Scientific Advisory Board. Dr. Loscalzo is chair of the Department of Medicine and physician-in-chief at Brigham and Women's Hospital (BWH). A cardiovascular medicine specialist, he is also the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School (HMS).
Applied BioMath (www.appliedbiomath.com), a computational partner applying quantitative methodologies at critical decision points throughout the drug invention process, announced that it will present and exhibit at the Drug Development Bootcamp onNovember 17-18, 2015 at The Harvard Club in Boston, MA.
Top Pharma and Biotech Researchers meet with local Academics for QSP-SB Industry & Academia Symposium
Applied BioMath (www.appliedbiomath.com) announces the kick-off of the 2015-2016 QSP-SB Industry & Academia Symposium series. This week, top pharma and biotech representatives will meet along with local faculty, students, and post docs, for the Fall QSP-SB Industry & Academia Symposium.
This publication appears in the October 2015 edition of Molecular Cancer Therapeutics
Applied BioMath, LLC. To Sponsor and Present at the Inaugural Quantitative Systems Pharmacology (QSP) Program at Discovery on Target 2015
Applied BioMath, a computational partner applying quantitative methodologies at critical decision points throughout the drug invention process, announced that it will sponsor and present at the Quantitative Systems Pharmacology (QSP) Program at Discovery on Target 2015 on September 23-24 in Boston, MA. Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present “QSP approaches enabling quantitative decisions in drug discovery from early research to clinical trials” on Thursday September 24, 2015 at 12:10 PM.
Applied BioMath cohosts Inaugural QSP/SB Academia-Industry Seminar with MIT Biological Engineering Department
Applied BioMath and the MIT Biological Engineering Department recently held the inaugural QSP/SB Academic-Industry Symposium at the MIT State Center in Camrbidge, MA. The QSP/SB Academic-Industry Symposium is an ongoing academic-industry forum to discuss systems biology and quantitative systems pharmacology projects, challenges, and opportunities.
New Applied BioMath Publication: An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates
Applied BioMath is proud to announce its most recent publication, An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates, published in the July 2015 edition of Pharmaceutical Research.
Applied BioMath presents at "Quantitative Systems Pharmacology: Progress Towards Integration into Drug Discovery and Development"
John M. Burke, PhD President, CEO and Co-founder of Applied BioMath will present a talk on "Quantitative Systems Approaches in Inflammation to Enable Decision Making in Early Discovery and Clinical Trials" at the "Quantitative Systems Pharmacology: Progress Towards Integration into Drug Discovery and Development" conference on May 26, 2015 at the New York Academy of Sciences.